Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Moderna Inc. MRNA

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:MRNA)

Fundamentals Snapshot (NDAQ:MRNA)

Current News (NDAQ:MRNA)

Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK

Accesswire 19 hours ago

Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses

Accesswire 7 days ago

Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates

Accesswire 12 days ago

Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses

Accesswire July 29, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

Accesswire July 22, 2022

Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years

Accesswire July 18, 2022

Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)

Accesswire July 14, 2022

Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022

Accesswire July 13, 2022

Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215

Accesswire July 12, 2022

Bullboard Posts (NDAQ:MRNA)

Moderna Shares Soar As Company Announces $3 Billion Stock Bu

Moderna Inc shares on Wednesday soared as high as 17% after it announced that it would be buying back up to US$3 billion of its stock...
AwareInvestor - 11 days ago

RE:News BioVaxys Confirms First Clinical Site and Principal In

Sounds very promising
Joe455 - May 29, 2022

News BioVaxys Confirms First Clinical Site and Principal In

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell...
frankman - May 18, 2022

BioVaxys CEO shares op ed - top Canadian political website
frankman - April 27, 2022

BioVaxys Enters Critical Tumor Cell Supply Agreement

For BVX-0918 Bioproduction VANCOUVER, BC, April 25, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV...
frankman - April 25, 2022

BioVaxys Expands Cancer Vaccine Platform

BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys...
johnfever21 - March 30, 2022